The Charcot-Marie-Tooth Disease Type II drugs in development market research report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Charcot-Marie-Tooth Disease Type II. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type II and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Charcot-Marie-Tooth Disease Type II by 12 companies/universities/institutes. The top development phase for Charcot-Marie-Tooth Disease Type II is preclinical with eight drugs in that stage. The Charcot-Marie-Tooth Disease Type II pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Charcot-Marie-Tooth Disease Type II pipeline products market are: Recursion Pharmaceuticals, Bristol-Myers Squibb and OliPass.
The key targets in the Charcot-Marie-Tooth Disease Type II pipeline products market include Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), Mitofusin 2 (Transmembrane GTPase MFN2 or MFN2 or EC 3.6.5.), and Transient Receptor Potential Cation Channel Subfamily V Member 4 (Osm 9 Like TRP Channel 4 or Vanilloid Receptor Like Protein 2 or TRPV4).
The key mechanisms of action in the Charcot-Marie-Tooth Disease Type II pipeline product include Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Inhibitor with four drugs in Phase I. The Charcot-Marie-Tooth Disease Type II pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Charcot-Marie-Tooth Disease Type II pipeline products market including Small Molecule, and Gene Therapy.
Charcot-Marie-Tooth Disease Type II overview
Charcot–Marie–Tooth disease (CMT) is a hereditary motor and sensory neuropathy of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body. Symptoms include Loss of touch sensation in the feet, ankles, and legs as well as in the hands, wrists, and arms occurs with various types of the disease. CMT can be diagnosed through three different forms of tests: measurement of the speed of nerve impulses (nerve conduction studies), a biopsy of the nerve, and DNA testing.
For a complete picture of Charcot-Marie-Tooth Disease Type II’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
